

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.

Date of Report: April 04, 2007
(Date of earliest event reported)

Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)

CA
(State or other jurisdiction
of incorporation)

000-50679
(Commission File
Number)

77-0487658
(IRS Employer
Identification Number)

149 Commonwealth Drive
(Address of principal executive offices)

94025
(Zip Code)

650-327-3270
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On April 4, 2007 Corcept Therapeutics issued a press release announcing that a Nasdaq Listing Qualifications Panel has granted the Company's request to be listed on the Nasdaq Capital Market.

Item 9.01. Financial Statements and Exhibits

(a) Financial statements:

None

(b) Pro forma financial information:

None

(c) Shell company transactions:

None

(d) Exhibits

99.1 [Press Release of Corcept Therapeutics Incorporated dated April 04, 2007](#)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 04, 2007

CORCEPT THERAPEUTICS INCORPORATED

By: /s/ /s/ Fred Kurland
/s/ Fred Kurland
Chief Financial Officer

Exhibit Index

Exhibit No.

Description

99.1

Press Release of Corcept Therapeutics Incorporated dated April
04, 2007

Nasdaq Panel Grants Corcept Therapeutics' Request for Listing on the Nasdaq Capital Market

MENLO PARK, CA -- 04/04/2007 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that a Nasdaq Listing Qualifications Panel has granted the company's request to be listed on the Nasdaq Capital Market, effective with the market opening on Monday, April 9, 2007. By transferring from the Nasdaq Global Market to the Nasdaq Capital Market, Corcept satisfies all listing requirements. The Company's trading symbol will remain CORT.

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases. Corcept's lead product, CORLUX®, is currently in Phase III clinical trials for the treatment of the psychotic features of PMD. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD. The Company is also conducting a proof-of-concept study evaluating the ability of CORLUX to mitigate weight gain associated with the use of olanzapine. For additional information about the company, please visit www.corcept.com.

Statements made in this news release, other than statements of historical fact, are forward-looking statements. Forward-looking statements are subject to a number of known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements. Examples of such forward-looking statements include statements regarding the pending listing of Corcept common stock on the NASDAQ Capital Market. These and other risk factors are set forth in the Company's SEC filings, all of which are available from our website (www.corcept.com) or from the SEC's website (www.sec.gov).

We disclaim any intention or duty to update any forward-looking statement made in this news release.

CONTACT:

Joseph K. Belanoff, M.D.
Chief Executive Officer
Corcept Therapeutics
650-327-3270
IR@corcept.com
www.corcept.com